Kevin Hykes is recorded as Board Member at CVRx, Inc. (CVRX) since January 1, 2022 and CEO at CVRx, Inc. (CVRX). The newest filing on record that lists Kevin Hykes as CEO and Board Member at CVRx, Inc. (CVRX) is dated April 20, 2026. CVRx, Inc. reported in an 8-K filed April 30, 2024 that Kevin Hykes was appointed Chief Executive Officer, effective February 12, 2024. CVRx, Inc. reported in an 8-K filed January 31, 2024 that Kevin Hykes was appointed President and Chief Executive Officer, effective February 12, 2024. CVRx, Inc. reported in an 8-K filed December 20, 2022 that Kevin Hykes was appointed director, effective December 21, 2022. The proxy statement of CVRx, Inc. reports total compensation of $8,756,626 for Kevin Hykes in fiscal 2024, including a base salary of $569,946. Kevin Hykes has spoken on 11 earnings calls and 3 other investor events across 1 company, most recently for CVRx, Inc. on November 5, 2026. CVRx, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at CVRx, Inc. includes John Landry (CFO), Brent Binkowski (COO), Continuing Directors (Board Member) and 7 others.
“Kevin Hykes was appointed as Chief Executive Officer on February 12, 2024”
“On January 31, 2024, CVRx, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Kevin Hykes as President and Chief Executive Officer (“CEO”), effective February 12, 2024.”
CVRx, Inc. Form 8-K, filed January 31, 2024
· Read the filing
Kevin Hykes on recent calls
“We delivered total revenue of $13.8 million in the third quarter within our guidance range with a steady gross margin of 87%. Revenue declined 6.1% from the same quarter last year, with U.S. revenue down 4% and Europe down 27%.”
“I appreciate the chance to address the group today about the status of CVRX. These are our forward-looking statements. So just as a little bit of background here, CVRX is commercializing the world's first autonomic neuromodulation therapy to treat heart failure.”
“We delivered total revenue of $15.7 million in the second quarter, demonstrating growth of 16% over the same quarter last year, with a gross margin of 87%. Despite the positive quarter, we are seeing signs that the back half of the year will not be as strong as the first.”
“But just on behalf of the company, before I let him address that, we're thrilled after 11 years and significant, innumerable contributions, he's ready for his next chapter, which we fully support, and he's been extremely instructive, not surprisingly, in constructing this transition So we'll have him for another nine…”
“And what I'd like to share with you is our continued work on our plan to drive Barostim to standard of care for the treatment of this condition. Heart failure is a burdensome disease, affecting nearly 6.7 Americans alone.”
